ONCOSTELLAE

Oncostellae is a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary drug candidates with strong IP and worldwide rights targeting indications in oncology and immunology with high unmet medical need... Oncostellae is a biotechn startup developing small-molecule drugs with innovative scaffolds (NCEs) that modulate clinically validated therapeutic targets in oncology and inflammatory/autoimmune diseases... Our lead program is a novel, GI-targeted JAK inhibitor, OST-122, which is currently in clinical development for the treatment of IBD (Inflammatory Bowel Disease). OST-122 has been designed as a local treatment that is taken orally and acts exclusively in the gastrointestinal tract avoiding severe systemic toxicities inherent in other JAK inhibitors. Its excellent safety profile has been demonstrated in preclinical models, healthy volunteers during a successful phase 1 clinical trial, and currently in a phase 2a proof-of-concept study in..

Also known as: ONCOSTELLAE, S.L.

Primary location: Santiago De Compostela Spain